T1	HMM 198 223	efficacy and tolerability
T2	HMM 794 805	discretion.
T3	HMM 806 830	The primary endpoint was
T4	HMM 877 923	secondary endpoints were changes from baseline
T5	HMM 1279 1293	p < 0.001)
T6	HMM 1382 1418	weight vs placebo (all p < 0.01)
T7	HMM 1477 1491	blood pressure
T8	HMM 1528 1565	percentages of patients had confirmed
T9	HMM 1671 1693	15 and 12% of patients
T10	HMM 1803 1823	and 5%, respectively
T11	HMM 1825 1850	CONCLUSIONS Empagliflozin
T12	HMM 1855 1880	78 weeks added to basal
